Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: DETROL

« Back to Dashboard

Summary for Tradename: DETROL

Patents:3
Applicants:1
NDAs:2
Suppliers: see list4

Pharmacology for Tradename: DETROL

Clinical Trials for: DETROL

Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
Status: Completed Condition: Overactive Bladder

A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Recruiting Condition: Overactive Bladder (OAB)

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
Status: Completed Condition: Healthy

Efficacy and Safety Study of Dutasteride Combined With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
Status: Active, not recruiting Condition: BPH

Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine
Status: Completed Condition: Pharmacokinetics of Mirabegron and Tolterodine; Healthy

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
Status: Terminated Condition: Urinary Incontinence

Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients
Status: Completed Condition: Overactive Bladder

A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
Status: Completed Condition: Overactive Bladder

Pharmacokinetics and Relative Bioavailability Study
Status: Completed Condition: Urinary Bladder, Overactive

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
Status: Completed Condition: Healthy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
DETROL
tolterodine tartrate
TABLET;ORAL020771Mar 25, 1998RXNo<disabled><disabled>
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228Dec 22, 2000RXYes6,770,295*PED<disabled>Y<disabled>
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228Dec 22, 2000RXNo6,911,217*PED<disabled>Y<disabled>
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228Dec 22, 2000RXNo6,630,162*PED<disabled>Y<disabled>
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228Dec 22, 2000RXYes6,630,162*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: DETROL

Drugname Dosage Strength RLD Submissiondate
tolterodine tartrateTablets1 mg and 2 mgDetrol 
tolterodine tartrateExtended-release Capsules2 mg and 4 mgDetrol LA7/30/2007
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc